Loading...

Neogen Corporation

NEOGNASDAQ
Healthcare
Medical - Diagnostics & Research
$5.64
$0.04(0.71%)

Neogen Corporation (NEOG) Financial Performance & Income Statement Overview

Explore the financials of Neogen Corporation (NEOG), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
12.37%
12.37%
Operating Income Growth
56.37%
56.37%
Net Income Growth
58.81%
58.81%
Operating Cash Flow Growth
-14.05%
14.05%
Operating Margin
-118.59%
118.59%
Gross Margin
47.10%
47.10%
Net Profit Margin
-122.06%
122.06%
ROE
-41.46%
41.46%
ROIC
-32.45%
32.45%

Neogen Corporation (NEOG) Income Statement & Financial Overview

View the income breakdown for Neogen Corporation NEOG across both annual and quarterly reports.

MetricQ3 2025Q2 2025Q1 2025Q4 2024
Revenue$220.98M$231.26M$216.96M$236.79M
Cost of Revenue$110.72M$117.93M$112.04M$123.31M
Gross Profit$110.27M$113.33M$104.93M$113.48M
Gross Profit Ratio$0.50$0.49$0.48$0.48
R&D Expenses$4.47M$5.11M$5.20M$5.14M
SG&A Expenses$100.38M$104.32M$97.47M$95.30M
Operating Expenses$104.85M$570.81M$102.67M$95.91M
Total Costs & Expenses$215.56M$688.74M$214.71M$219.22M
Interest Income$699000.00$774000.00$993000.00$1.10M
Interest Expense$17.74M$18.14M$18.61M$18.62M
Depreciation & Amortization$29.37M$749000.00$29.80M$28.86M
EBITDA$37.38M-$457.48M$32.81M$41.67M
EBITDA Ratio$0.17-$1.98$0.15$0.18
Operating Income$5.42M-$457.48M$2.26M$17.57M
Operating Income Ratio$0.02-$1.98$0.01$0.07
Other Income/Expenses (Net)-$15.14M-$19.09M-$17.87M-$19.44M
Income Before Tax-$9.73M-$476.57M-$15.61M-$6.40M
Income Before Tax Ratio-$0.04-$2.06-$0.07-$0.03
Income Tax Expense$1.23M-$20.29M-$3.00M-$984000.00
Net Income-$10.96M-$456.28M-$12.61M-$5.42M
Net Income Ratio-$0.05-$1.97-$0.06-$0.02
EPS-$0.05-$2.10-$0.06-$0.03
Diluted EPS-$0.05-$2.10-$0.06-$0.03
Weighted Avg Shares Outstanding$217.03M$216.81M$216.70M$216.61M
Weighted Avg Shares Outstanding (Diluted)$217.03M$216.81M$216.70M$216.61M

Over the past four quarters, Neogen Corporation demonstrated steady revenue growth, increasing from $236.79M in Q4 2024 to $220.98M in Q3 2025. Operating income reached $5.42M in Q3 2025, maintaining a consistent 2% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $37.38M, reflecting operational efficiency. Net income rose to -$10.96M, with EPS at -$0.05. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;